IMR Press / FBS / Volume 1 / Issue 2 / DOI: 10.2741/S33

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Chemokines and cardiac fibrosis
Show Less
1 Section of Cardiovascular Sciences, Baylor College of Medicine, One Baylor Plaza BCM620, Houston TX 77030 USA

*Author to whom correspondence should be addressed.

Academic Editor: Steven Dooley

Front. Biosci. (Schol Ed) 2009, 1(2), 391–405; https://doi.org/10.2741/S33
Published: 1 June 2009
(This article belongs to the Special Issue TGF-beta in fibroproliferative diseases)
Abstract

Several members of the chemokine family play an important role in reparative fibrosis and are involved in the pathogenesis of remodeling following myocardial infarction. Chemokines may regulate the fibrotic process through recruitment and activation of mononuclear cell subsets and fibroblast progenitors (fibrocytes), by exerting direct effects on resident fibroblasts, and by modulating angiogenesis. Monocyte Chemoattractant Protein (MCP)-1/CCL2 is the best studied chemokine in cardiac fibrosis. Disruption of the MCP-1 axis reduces fibrosis attenuating dilation of the infarcted ventricle. In addition, MCP-1 signaling is activated in response to insults that do not cause cardiomyocyte death, such as brief ischemia or pressure overload and regulates fibrous tissue deposition in experimental models of fibrotic non-infarctive cardiomyopathy. Understanding the role of chemokine-mediated interactions in the development of cardiac fibrosis may identify novel therapeutic targets for treatment of patients with heart failure.

Share
Back to top